Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Bottom Line: Cognitive outcomes remained higher in the early treated patients.EDSS remained low over time with a median of 1.5 in both arms.These 8-year results provide further evidence supporting early initiation of treatment with IFNB1b in patients with a first event suggestive of MS.
Affiliation: University of Rennes, Rennes, France.Show MeSH
Related in: MedlinePlus
Mentions: All 468 patients randomised and treated at least once with study medication in the placebo-controlled phase were eligible to enter the observational extension study in which treatment decisions were made exclusively at the discretion of physicians and patients. Physicians recorded any medications for MS that were administered. Prior to the end of the BENEFIT Extension study, the steering committee identified a list of therapies that were defined as DMTs. Of this list, a subset was considered as escalation therapy (figure 1).